-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Shanghai Pharmaceutical Industry Association released the 2020 Shanghai Pharmaceutical Industry Famous Products List, and Han Likang® (rituximab) and Han Quyou® (trastuzumab) independently developed by Henlius were reviewed by the approval committee.
Experts unanimously affirmed that Shuangshuang was rated as "2020 Shanghai Pharmaceutical Industry Famous Product"
.
In order to further implement the spirit of Shanghai’s “Guiding Opinions on Strengthening Quality Brand Building and Promoting High-Quality Development”, to implement the promotion strategy of Shanghai’s “Four Major Brands”, and to promote the brand development of the pharmaceutical industry, the Shanghai Pharmaceutical Industry Association organized and launched the “Shanghai Pharmaceutical Industry Association”.
"Industry Famous Products" application review work
.
The Association established the Shanghai Pharmaceutical Industry Famous and High-quality Product Approval Committee, and specially hired review experts to assess the applicants and companies from six aspects: corporate innovation capability, quality infrastructure construction, quality management, corporate economic scale and sustainable development, corporate image, and product construction results.
Han Likang® (rituximab) is the first product independently developed by the company.
It was approved by the China National Medical Products Administration (NMPA) in February 2019.
It is China’s first biosimilar drug that can be used in non- The approval of the treatment of Hodgkin's lymphoma and chronic lymphocytic leukemia breaks the pattern of China's monoclonal antibody industry and fills the gap in China's biosimilar drug market
.
Since its launch for more than two years, Han Likang® has benefited more than 50,000 Chinese patients.
Han Likang® (rituximab)
Hanquyou® (trastuzumab, EU trade name: Zercepac®) is the company’s core product in the field of anti-tumor therapy.
It was approved by the European Commission (EC) and NMPA in July and August 2020 for Treatment of HER2-positive breast and gastric cancer
.
Hanquyou® opened a new chapter in the internationalization of China's biomedical R&D achievements with its quality compliant with international standards, and opened up a precedent for Chinese pharmaceutical companies to participate in the "World Cup" competition for monoclonal antibody biosimilars
Hanquyou® (trastuzumab, EU trade name: Zercepac®)
This time, Hanlikang® and Hanquyou® were awarded the "2020 Shanghai Pharmaceutical Industry Famous Products", which is a great recognition of these two products and Fuhong Henlius
.
In the future, Henlius will continue to accelerate the process of launching pipeline products, cooperate with scientific research centers in China and the United States to improve research and development efficiency, and continue to increase diversified innovations.
